Neurizon Therapeutics (ASX: NUZ) Advances ALS Treatment Towards Pivotal 2027 Results as $12 Million Funding Facility Strengthens Outlook

Neurizon Therapeutics (ASX: NUZ) is building momentum towards a potentially transformative clinical milestone, with two developments on 13 November 2026 strengthening its position ahead of pivotal ALS treatment results.

The company has confirmed that the first participant entered the Active Treatment Extension of its Phase 2/3 HEALEY ALS Platform Trial, while a further $3.7 million financing drawdown increased total funding accessed through its research and development facility to approximately $12 million.

Together, these developments highlight improving clinical execution and greater financial flexibility as Neurizon advances its lead drug candidate, NUZ-001, towards results anticipated in late Q2 CY2027.

Key numbers

• 250 participants: Fully enrolled across 78 US clinical sites in approximately five months.
• 36 weeks: Randomised controlled treatment, followed by an optional 36-week extension.
• $12 million: Total drawn under the Dare Capital R&D financing facility, including the latest $3.7 million advance.
• $11.4 million: Cash held at 30 September 2026, with $7.9 million in quarterly operating cash outflows.
• $4.3 million: November equity placement, alongside a proposed $2 million share purchase plan.

First patient milestone strengthens clinical development momentum

Neurizon's latest clinical announcement confirms that the first Regimen I participant has completed the trial's 36-week randomised controlled phase and transitioned into the Active Treatment Extension.

The extension allows eligible participants to receive NUZ-001 regardless of their original treatment allocation, providing an opportunity to gather additional evidence through longer-term treatment exposure.

Researchers will continue monitoring functional decline, respiratory function, quality of life and biomarkers, including neurofilament light chain, which is associated with nerve damage.

These observations could strengthen the evidence package supporting NUZ-001's future regulatory development.

Importantly, the milestone follows the successful enrolment of 250 participants across 78 US clinical sites in approximately five months, demonstrating strong trial recruitment and execution.

While the extension does not independently establish treatment effectiveness, it represents meaningful progress towards completing the broader clinical programme.

FDA feedback opens a promising regulatory opportunity

Neurizon's clinical progress follows encouraging written feedback from the US Food and Drug Administration in October 2026.

The regulator indicated that positive results from the HEALEY trial could support a traditional approval pathway, potentially allowing Regimen I to serve as a single registrational study.

This is particularly significant because it could reduce the need for an additional major efficacy trial, potentially shortening the development pathway if the results and supporting evidence satisfy regulatory requirements.

Neurizon is also progressing preparations for an NIH-funded Expanded Access Program, expected to begin enrolling participants in Q1 CY2027.

The programme is designed to provide NUZ-001 to approximately 200 people living with ALS for up to 96 weeks, supporting the collection of longer-term safety information.

Together, these initiatives could broaden the clinical evidence available to support future regulatory engagement.

$12 million facility provides greater financial flexibility

Neurizon's second announcement on 13 November extends its Dare Capital financing arrangement to cover eligible FY2027 research and development expenditure.

Following an initial $8.3 million drawdown in August, the latest $3.7 million advance brings total drawings to approximately $12 million.

The facility allows Neurizon to access expected Australian R&D tax refunds before receiving reimbursement from the Australian Taxation Office.

Crucially, this financing arrangement does not require additional equity issuance, helping reduce reliance on potentially dilutive funding sources.

The facility carries interest of 1.25% per month, capitalised until repayment following receipt of the relevant refunds.

At 30 September 2026, Neurizon held $11.4 million in cash, while quarterly operating outflows totalled $7.9 million.

Its FY2026 net loss narrowed to approximately $10.7 million from $16.6 million in FY2025, although annual operating cash outflows increased from $14.3 million to $15.1 million.

The company's recent equity placement, alongside the redemption of outstanding Obsidian convertible notes, further supports a simplified financing structure.

Although clinical development remains capital-intensive, these funding initiatives provide additional flexibility as Neurizon approaches its anticipated trial readout.

Insight: Clinical progress and funding flexibility create a compelling 2027 catalyst

What stands out to us is Neurizon's increasingly coordinated approach to clinical development, regulatory preparation and financing. With 250 trial participants enrolled and approximately $12 million accessed through its R&D facility, the company has made tangible progress towards a potentially important clinical milestone. Encouraging FDA feedback adds significance to the opportunity, particularly if positive results can support a single registrational study. We see considerable potential in this progress, with the late Q2 CY2027 topline readout providing the clearest test of NUZ-001's prospects.

The verdict: Neurizon is positioning for a potentially defining year

Neurizon enters its next development phase with encouraging clinical momentum, improved funding flexibility and a potentially more efficient regulatory pathway.

While NUZ-001 remains investigational and further financing may be required, the combination of completed enrolment, regulatory engagement and additional funding supports a constructive outlook.

The next major milestones include completing randomised treatment, database lock and delivering topline results in late Q2 CY2027.

If NUZ-001 demonstrates convincing clinical benefits, Neurizon could move materially closer to regulatory approval and unlock a significant new stage in its commercial development.